These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34996468)

  • 21. Assessment of global and regional left ventricular volume and shape by real-time 3-dimensional echocardiography in dogs with myxomatous mitral valve disease.
    Ljungvall I; Höglund K; Carnabuci C; Tidholm A; Häggström J
    J Vet Intern Med; 2011; 25(5):1036-43. PubMed ID: 21848946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blinded, controlled trial of the effects of coenzyme Q
    Druzhaeva N; Petrič AD; Tavčar-Kalcher G; Babič J; Nemec Svete A
    Am J Vet Res; 2021 Apr; 82(4):280-285. PubMed ID: 33764833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
    Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic management of myxomatous mitral valve disease in dogs.
    Atkins CE; Häggström J
    J Vet Cardiol; 2012 Mar; 14(1):165-84. PubMed ID: 22386553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
    Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
    J Am Heart Assoc; 2021 May; 10(9):e018923. PubMed ID: 33890477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
    J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs.
    Pirintr P; Saengklub N; Boonpala P; Hamlin RL; Kijtawornrat A
    BMC Vet Res; 2023 Oct; 19(1):201. PubMed ID: 37821927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Left ventricular twist and circumferential strain in dogs with myxomatous mitral valve disease.
    Zois NE; Olsen NT; Moesgaard SG; Rasmussen CE; Falk T; Häggström J; Pedersen HD; Møller JE; Olsen LH
    J Vet Intern Med; 2013; 27(4):875-83. PubMed ID: 23731222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease.
    Ljungvall I; Rajamäki MM; Crosara S; Olsen LH; Kvart C; Borgarelli M; Höglund K; Häggström J
    Am J Vet Res; 2011 Aug; 72(8):1022-8. PubMed ID: 21801058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Echocardiographic estimation of left ventricular-arterial coupling in dogs with myxomatous mitral valve disease.
    Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2021 Jan; 35(1):78-87. PubMed ID: 33442907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Newhard DK; Jung S; Winter RL; Duran SH
    J Vet Intern Med; 2018 Sep; 32(5):1555-1563. PubMed ID: 30084228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
    Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
    J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
    Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
    Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective evaluation of the utility of shock index to determine the presence of congestive heart failure in dogs with myxomatous mitral valve disease (2019-2021): 98 cases.
    Matson H; Llewellyn EA
    J Vet Emerg Crit Care (San Antonio); 2024; 34(3):231-237. PubMed ID: 38809224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease.
    Mikawa S; Nagakawa M; Ogi H; Akabane R; Koyama Y; Sakatani A; Ogawa M; Miyakawa H; Shigemoto J; Tokuriki T; Toda N; Miyagawa Y; Takemura N
    J Vet Cardiol; 2020 Aug; 30():92-99. PubMed ID: 32707334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left atrial ejection fraction assessed by real-time 3-dimensional echocardiography in normal dogs and dogs with myxomatous mitral valve disease.
    Tidholm A; Höglund K; Häggström J; Bodegård-Westling A; Ljungvall I
    J Vet Intern Med; 2013; 27(4):884-9. PubMed ID: 23731204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.